AI Therapeutics Announces Start of Phase II Trial of LAM-002A
27 Jul 2020 //
BUSINESSWIRE
AI Therapeutics Announces Start of Ph II Trial of LAM-002A (apilimod dimesylate)
27 Jul 2020 //
BUSINESSWIRE
27 Jul 2020 //
BUSINESSWIRE
27 Jul 2020 //
BUSINESSWIRE